Century Therapeutics Inc

NASDAQ IPSC

Data sourced from

and

Daily

Download Data

Century Therapeutics Inc Market Capitalization on June 03, 2024: USD 247.87 M

Century Therapeutics Inc Market Capitalization is USD 247.87 M on June 03, 2024, a 31.53% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Century Therapeutics Inc 52-week high Market Capitalization is USD 324.74 M on March 20, 2024, which is 31.01% above the current Market Capitalization.
Century Therapeutics Inc 52-week low Market Capitalization is USD 309.44 K on March 11, 2024, which is -99.88% below the current Market Capitalization.
Century Therapeutics Inc average Market Capitalization for the last 52 weeks is USD 186.10 M.

NASDAQ: IPSC

Century Therapeutics Inc

CEO	Dr. Osvaldo Flores Ph.D.
IPO Date	June 18, 2021
Location	United States
Headquarters	3675 Market Street, Philadelphia, PA, United States, 19104
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key trends